MRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Mirati Therapeutics's change in receivables for the quarter that ended in Sep. 2023 was $-4.13 Mil. It means Mirati Therapeutics's Accounts Receivable increased by $4.13 Mil from Jun. 2023 to Sep. 2023 .
Mirati Therapeutics's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.87 Mil. It means Mirati Therapeutics's Accounts Receivable increased by $0.87 Mil from Dec. 2021 to Dec. 2022 .
Mirati Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2023 was $14.65 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Mirati Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2023 was 81.52.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mirati Therapeutics's liquidation value for the three months ended in Sep. 2023 was $814.26 Mil.
The historical data trend for Mirati Therapeutics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirati Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | -0.87 |
Mirati Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | -5.36 | -4.30 | -4.13 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirati Therapeutics (NAS:MRTX) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Mirati Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 14.651 | / | 16.4 | * | 91 |
= | 81.52 |
2. In Ben Graham's calculation of liquidation value, Mirati Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Mirati Therapeutics's liquidation value for the quarter that ended in Sep. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 976.434 | - | 183.243 | + | 0.75 * 14.651 | + | 0.5 * 20.156 |
= | 814.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Mirati Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Jamie Christensen | officer: Sr. Vice President, Chief Scie | C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: EVP, Chief Commercial Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
Aaron Ondrey | officer: Interim CFO | 3545 CRAY COURT, SAN DIEGO CA 92121 |
Boxer Capital, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Christopher Fuglesang | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Shehan Bharatha Dissanayake | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Aaron I. Davis | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Mva Investors, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Boxer Asset Management Inc. | other: See remarks | CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000 |
Joseph Lewis | other: See remarks | PO BOX N7776, LYFORD BAHAMAS |
Faheem Hasnain | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John B Moriarty | officer: Chief Legal Officer | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Laurie Stelzer | officer: CFO | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Julie M Cherrington | director | 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 12-20-2023
By Marketwired • 10-09-2023
By PRNewswire • 09-10-2023
By PRNewswire • 11-14-2023
By GuruFocus Research • 11-06-2023
By PRNewswire • 10-26-2023
By PRNewswire • 01-10-2024
By PRNewswire • 08-10-2023
By PRNewswire • 08-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.